UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000034321
Receipt number R000039126
Scientific Title A retrospective study of interstitial lung disease due to EGFR tyrosine kinase inhibitor and immune checkpoint inhibitor
Date of disclosure of the study information 2018/10/01
Last modified on 2021/04/07 17:38:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A retrospective study of interstitial lung disease due to EGFR tyrosine kinase inhibitor and immune checkpoint inhibitor

Acronym

NEJ040

Scientific Title

A retrospective study of interstitial lung disease due to EGFR tyrosine kinase inhibitor and immune checkpoint inhibitor

Scientific Title:Acronym

NEJ040

Region

Japan


Condition

Condition

non-small cell lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate reasonable sequence and interval to use EGFR tyrosine kinase inhibitor and immune checkpoint inhibitor for patients with non-small cell lung cancer harboring EGFR mutation

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Relationships between sequence/interval to use EGFR tyrosine kinase inhibitor and immune checkpoint inhibitor, and frequency/severity of interstitial lung disease

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.non-small cell lung cancer with EGFR mutations
2.To have treatment history using EGFR tyrosine kinase inhibitor and immune check poinnt inhibitor

Key exclusion criteria

non

Target sample size

300


Research contact person

Name of lead principal investigator

1st name Kazuhisa
Middle name
Last name Takahashi

Organization

Juntendo University

Division name

Department of Respiratory Medicine

Zip code

113-8431

Address

Hongo 2-1-1, Bunkyo-ku, Tokyo

TEL

03-3813-3111

Email

kztakaha@juntendo.ac.jp


Public contact

Name of contact person

1st name Ryo
Middle name
Last name Ko

Organization

Juntendo University

Division name

Department of Respiratory Medicine

Zip code

113-8431

Address

Hongo 2-1-1, Bunkyo-ku, Tokyo

TEL

03-3813-3111

Homepage URL


Email

rkou@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University

Institute

Department

Personal name



Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Juntendo IRB

Address

Hongo 3-1-3, Bunkyo-ku, Tokyo

Tel

03-3813-3111

Email

kenkyu5858@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

235

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 08 Month 07 Day

Date of IRB

2018 Year 09 Month 20 Day

Anticipated trial start date

2018 Year 10 Month 01 Day

Last follow-up date

2020 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Survey Components

Patient characteristics, information of survival, information of treatment, information of interstitial lung disease


Management information

Registered date

2018 Year 09 Month 29 Day

Last modified on

2021 Year 04 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039126


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name